Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here's Why

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) is one of the best cheap biotech stocks to buy now. Guggenheim lifted the price target on Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) to $25 from $20 on February 27, maintaining a Buy rating on the shares and telling investors that it updated its model to reflect fiscal Q4 financials, and continues to be “encouraged” by the company’s goal to achieve profitability in early Q3 of 2026.

The rating update came after Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) announced its fiscal Q4 and full-year 2025 results on February 26. It reported over 1.1 million total VOQUEZNA® prescriptions filled to date, and stated that the net revenues for fiscal Q4 came up to $57.6 million and that for FY25 were $175.1 million, reflecting a 217% increase from FY24. Fiscal Q4 operating expenses came up to $55.9 million, with non-GAAP operating expenses of $50.3 million and net cash usage of approximately $5.2 million, reflecting continued expense discipline. Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) also bolstered its financial position through a $130 million equity offering and modification of term debt.

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) is a clinical-stage biopharmaceutical company that develops and commercializes novel treatments for gastrointestinal diseases.